688105 Nanjing Vazyme Biotech
- 23.01
- +0.13+0.57%
Nanjing Vazyme Biotech News
Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
Novizan (688105.SH): A cumulative repurchase of 1.01% of the company's shares at a cost of 98.4017 million yuan
Glonghui, May 13, 丨 Novizan (688105.SH) announced that as of May 10, 2024, the company had repurchased a total of 4,0282 million shares through the Shanghai Stock Exchange system, accounting for 1.01% of the company's total share capital of 400,010,000 shares. The lowest price for the repurchase transaction was 22.63 yuan/share, the highest price was 28.65 yuan/share, and the cumulative payment amount was 98.4017 million yuan (excluding transaction fees).
A subsidiary of Novizan (688105.SH) and a subsidiary of Shanghai Pharmaceutical reached a cooperation on businesses such as Alzheimer's disease blood test products
Novi Zan (688105.SH) announced that Nanjing Novi Zan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company (“Novi...
Novizan (688105.SH) reported first-quarter results, net profit of RMB 5.216,400
Novizan (688105.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Novizan (688105.SH): Net profit of 4.5 million yuan to 5.5 million yuan for the first quarter is expected to turn a year-on-year loss into a profit
On April 17, GLONGHUI (688105.SH) announced that the first quarter of 2024 achieved operating revenue of 30,000 million yuan to 315 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will increase by -219 million yuan to 12.81 million yuan, an increase of -0.7% to 4% over the previous year. Net profit attributable to owners of the parent company was 4.5 million yuan to 5.5 million yuan in the first quarter of 2024. Compared with the same period last year (statutory disclosure data), it will increase 55.12 million yuan to 56.12 million yuan, an increase of 109% to 111% over the previous year, turning a loss into a profit. 20
Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14%
Nanjing Vazyme Biotech(SHA:688105) has secured registration certificates for six new medical devices developed by its unit, Nanjing Novozan Medical Technology, according to a Monday filing on the Shan
Novizan (688105.SH) subsidiary develops AD series diagnostic reagent products to obtain medical device registration certificate
Zhitong Finance App News, Novizan (688105.SH) announced that a series of diagnostic reagent products developed by Nanjing Novizan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained a “Medical Device Registration Certificate”, namely beta amyloid 1-40 (Aβ1-40) test kit (chemiluminescence method), beta amyloid 1-42 (Aβ1-42) test kit (chemiluminescence method), phosphorylated Tau217 protein (p-TAU217) test kit (chemiluminescence method, phosphorylated Tau181 protein (Tau181 protein) p- Tau181) test kit (chemical
Novizan (688105.SH) subsidiary and Yufang Medical reached a strategic cooperation in the field of AD blood testing
Zhitong Finance App News, Novi Zan (688105.SH) issued an announcement. In order to implement the Health China Action Plan, comprehensively strengthen and deepen strategic cooperation between the two sides in screening and testing business, and actively promote the health and welfare of the public, the company's wholly-owned subsidiary Nanjing Novi Zan Medical Technology Co., Ltd. (“Novi Zan Medical” or “Party A”) recently signed a “Strategic Cooperation Agreement” with Shanghai Yufang Medical Technology (Group) Co., Ltd. (“Yufang Medical” or “Party B” for short) on strategic cooperation between the two parties in the screening and testing business. Relying on their respective industry positions and resource advantages, the two sides follow the “prevention is greater than cure”
Novizan (688105.SH): A total cost of 56.9 million yuan to buy back 0.6% of the shares
Glonghui, April 1, 丨 Novizan (688105.SH) announced that as of March 29, 2024, Nanjing Novizan Biotechnology Co., Ltd. had repurchased 2,393,058 shares of the company's shares through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.60% of the company's total share capital of 400,010,000 shares. The highest price of the repurchase transaction was 25.00 yuan/share, the lowest price was 22.63 yuan/share, and the total amount of capital paid was RMB 56,902,963.07 (excluding transaction fees).
Private Companies Invested in Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) Copped the Brunt of Last Week's CN¥456m Market Cap Decline
Key Insights The considerable ownership by private companies in Nanjing Vazyme BiotechLtd indicates that they collectively have a greater say in management and business strategy A total of 3 investo
Novizan (688105.SH): A total of 710,000 shares have been repurchased
Glonghui, March 1, 丨 Novi Zan (688105.SH) announced that as of February 29, 2024, the company had repurchased 710,000 shares of the company's shares through centralized bidding transactions, accounting for 0.18% of the company's total share capital of 400,010,000 shares. The highest price of the repurchase transaction was 25.00 yuan/share, the lowest price was 23.54 yuan/share, and the total amount of capital paid was RMB 17,238,348.68 (excluding transaction fees).
Nanjing Vazyme Biotech Swings to Loss in 2023
Nanjing Vazyme Biotech (SHA:688105) incurred a loss attributable to owners of 70.7 million yuan, or 0.18 yuan per share, in 2023, swinging from the year-ago profit of 594.2 million yuan, or 1.49 yuan
Novizan (688105.SH): Net loss of 706.974 million yuan in 2023
Glonghui, Feb. 28 | Novi Zan (688105.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 1,287 billion yuan, a year-on-year decrease of 63.94%; realized net profit attributable to owners of the parent company - 76.974 million yuan, a year-on-year decrease of 111.90%; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses - 190 million yuan, a year-on-year decrease of 131.79%.
Novizam (688105.SH): 250,000 shares repurchased for the first time
Glonghui, Feb. 19 | Novi Zan (688105.SH) announced that on February 19, 2024, the company repurchased 250,000 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0625% of the company's total share capital. The highest price of the repurchase transaction was 24.09 yuan/share, the lowest price was 23.54 yuan/share, and the total capital paid was RMB 5,977,496.99 (excluding transaction fees such as stamp duty and transaction commissions).
Novizan (688105.SH): Plans to repurchase 80 million yuan to 160 million yuan of company shares
On February 5, GLONGHUI (688105.SH) announced that it plans to repurchase the company's shares with a total capital of RMB 80 million to RMB 160 million. The repurchase price is no more than RMB 30 per share.
Investors Don't See Light At End Of Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Tunnel And Push Stock Down 27%
Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. The recent drop completes a
Novizan (688105.SH): Pre-loss of 60 million yuan to 75 million yuan in 2023
GLONGHUI, January 30丨Novi Zan (688105.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company is expected to achieve operating income of 1.26 million yuan to 1.3 million yuan in 2023. Compared with the same period of the previous year (statutory disclosure data), it will decrease by 2268.98 million yuan to 2.308.98 million yuan, a year-on-year decrease of 63.58% to 64.70%. Among them, the company expects to achieve operating income of 390.71 million yuan to 43.07 million yuan in the fourth quarter of 2023, and is expected to increase 92.45 million yuan to 13.24 million yuan over the previous month
Nanjing Vazyme BiotechLtd (SHSE:688105) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Novizan (688105.SH) and its subsidiaries have received a total of 95.5974 million yuan in grants
Novizam (688105.SH) issued an announcement. The company and related holding subsidiaries, from January 1, 2023 to...
Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) Surges 3.2%; Private Companies Who Own 51% Shares Profited Along With Insiders
Key Insights The considerable ownership by private companies in Nanjing Vazyme BiotechLtd indicates that they collectively have a greater say in management and business strategy A total of 3 investo
Analysis
Price Target
No Data
